Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

about

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

Item

http://www.wikidata.org/entity/Q36560960

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@ast

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@en

type

Item

label

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@ast

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@en

prefLabel

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@ast

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@en

P1476

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.

@en

P2093

Ashraf Aminorroaya

http://www.w3.org/2001/XMLSchema#string

Masoud Amini

http://www.w3.org/2001/XMLSchema#string

Saied Hossein Khalilzade

http://www.w3.org/2001/XMLSchema#string

Silva Hovsepain

http://www.w3.org/2001/XMLSchema#string

P2860

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

Type 2 diabetes mellitus, pandemic in 21st century.

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.

Bromocriptine: old drug, new formulation and new indication.

The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Choosing dopamine agonists in Parkinson's disease.

P304

253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2277-9175.170678

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

285385976

http://www.w3.org/2001/XMLSchema#string

P698

26918235

http://www.w3.org/2001/XMLSchema#string

P932

4746945

http://www.w3.org/2001/XMLSchema#string